The historical data trend for Novartis India's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NOVARTIND vs ZTS, UTHR: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Novartis India's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novartis India Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novartis India's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Novartis India's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novartis India (NSE:NOVARTIND) has a Buyback Yield % of 0.00 as of Jul. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Novartis India and its competitors. Over the past decade, Novartis India's Buyback Yield % has ranged from 15.38 to 15.47. According to the industry distribution chart, Novartis India ranks #999999 out of 290 companies in the Drug Manufacturers industry.
Is Novartis India's Buyback Yield % too high?
Novartis India's current Buyback Yield % is 0.00. Over the past 10 years, this metric has ranged from a low of 15.38 to a high of 15.47. Based on the distribution chart, Novartis India ranks #999999 out of 290 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Novartis India has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis India's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Novartis India ranks #999999 out of 290 companies for Buyback Yield %. This places Novartis India in the lower half of its industry. Historically, Novartis India's own Buyback Yield % has ranged from 15.38 to 15.47 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Novartis India and its competitors. Novartis India's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis India stock overvalued right now?
Based on GuruFocus' analysis, Novartis India (NSE:NOVARTIND) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹642.38, compared to a current price of ₹1,494.60 — trading 132.7% above its estimated fair value. The current Buyback Yield % is 0.00. Novartis India's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Novartis India (NSE:NOVARTIND), the current Buyback Yield % is 0.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novartis India (NSE:NOVARTIND) Overvalued in 2026?
Based on GuruFocus' analysis, Novartis India stock appears to be overvalued.
The current stock price of ₹1,494.60 is trading 132.7% above its estimated GF Value™ of ₹642.38.
GuruFocus considers Novartis India to be Significantly Overvalued.
Key valuation signals for NSE:NOVARTIND:
Buyback Yield %: 0.00
GF Value™: ₹642.38 vs. price of ₹1,494.60 (132.7% above fair value)
No single metric tells the full story. See the NSE:NOVARTIND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
62GF Score
Get the complete analysis for NSE:NOVARTIND
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NOVARTIND has been successfully added to your 
